-4.34%
6.47%
3.47%
16.62%
-10.88%
-71.97%
-77.23%
AI Spotlight on ONT
Company Description
Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules.The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing.It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data.
In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products.It sells its products online.The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008.
Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.
Market Data
| Last Price | 139.47 |
| Change Percentage | -4.34% |
| Open | 142.9 |
| Previous Close | 145.8 |
| Market Cap ( Millions) | 1332 |
| Volume | 707125 |
| Year High | 169.2 |
| Year Low | 85 |
| M A 50 | 142.35 |
| M A 200 | 128.08 |
Financial Ratios
| FCF Yield | -11.10% |
| Dividend Yield | 0.00% |
| ROE | -26.50% |
| Debt / Equity | 8.07% |
| Net Debt / EBIDTA | 88.33% |
| Price To Book | 2.08 |
| Price Earnings Ratio | -7.55 |
| Price To FCF | -9.01 |
| Price To sales | 7.94 |
| EV / EBITDA | -9.32 |
News
- Dec -05 - FTSE 100 reshuffle sees Vistry kicked out and Games Workshop join the UK blue-chip index
- Dec -03 - FTSE 100 reshuffle to see Vistry kicked out and Games Workshop join the UK blue-chip index
- Sep -03 - Oxford Nanopore Eyes FTSE 250 Inclusion to Widen Investor Base
- Aug -08 - Aligos Therapeutics Strengthens Board with Two New Independent Directors
- Aug -05 - Oxford Nanopore Technologies plc (LON:ONT) is largely controlled by institutional shareholders who own 50% of the company
- May -10 - Stocks to watch this week: Burberry, Vodafone, BT and Walmart
- Apr -26 - Stocks to watch this week: Amazon, Apple, Anglo American and Novo Nordisk
- Mar -25 - Trending tickers: Bitcoin, Baidu, Direct Line and Kingfisher
- Mar -10 - Oxford Nanopore Technologies Non-Executive Chair Acquires 84% More Stock
- Mar -09 - Oxford Nanopore Technologies plc (LON:ONT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- Nov -28 - This Oxford Nanopore Technologies Insider Increased Their Holding By 56% Last Year
- Nov -09 - We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
- Sep -08 - Oxford Nanopore Technologies First Half 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Sep -08 - Oxford Nanopore Technologies First Half 2023 Earnings: Revenues Beat Expectations, EPS Lags
- May -05 - Market Participants Recognise Oxford Nanopore Technologies plc's (LON:ONT) Revenues
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Life Science Research Tools
Expected Growth : 10.47 %
What the company do ?
Life Science Research Tools from Oxford Nanopore Technologies plc provide portable, real-time DNA/RNA sequencing and analysis solutions for researchers and scientists.
Why we expect these perspectives ?
Oxford Nanopore Technologies plc's Life Science Research Tools segment growth is driven by increasing adoption of portable, real-time sequencing technology, expanding applications in genomics, epigenomics, and transcriptomics, and growing demand for rapid, accurate, and cost-effective DNA sequencing solutions in research and diagnostics.
Oxford Nanopore Technologies Plc Products
| Product Range | What is it ? |
|---|---|
| MinION | A portable, real-time, long-read sequencer that can be used in a variety of settings, including laboratories, hospitals, and even in the field. |
| PromethION | A high-throughput, real-time sequencer that can process multiple flow cells simultaneously, ideal for large-scale genomics and transcriptomics projects. |
| Flongle | A low-cost, portable adapter that enables real-time sequencing on the MinION, ideal for small-scale sequencing projects and proof-of-concept studies. |
| VolTRAX | A sample preparation device that automates the preparation of DNA libraries for sequencing, ideal for high-throughput sequencing projects. |
| Nanopore sequencing kits | A range of kits that provide the necessary reagents and consumables for sequencing on Oxford Nanopore Technologies' platforms. |
Oxford Nanopore Technologies plc's Porter Forces
Threat Of Substitutes
Oxford Nanopore Technologies plc has a low threat of substitutes due to its unique and proprietary sequencing technology, which provides a high level of accuracy and portability.
Bargaining Power Of Customers
The bargaining power of customers is moderate, as Oxford Nanopore Technologies plc has a diverse customer base, including research institutions, hospitals, and biotech companies, which reduces dependence on a single customer.
Bargaining Power Of Suppliers
The bargaining power of suppliers is low, as Oxford Nanopore Technologies plc has a diversified supply chain and is not heavily dependent on a single supplier.
Threat Of New Entrants
The threat of new entrants is high, as the sequencing market is attractive and has low barriers to entry, which may lead to new competitors entering the market.
Intensity Of Rivalry
The intensity of rivalry is high, as Oxford Nanopore Technologies plc operates in a highly competitive market with established players, such as Illumina and PacBio, which may lead to price wars and intense competition.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.08% |
| Debt Cost | 5.13% |
| Equity Weight | 93.92% |
| Equity Cost | 7.13% |
| WACC | 7.00% |
| Leverage | 6.47% |
Oxford Nanopore Technologies plc : Quality Control
Oxford Nanopore Technologies plc passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHARM.AS | Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, … |
| EVGN | Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through … |
| IMTX | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company … |
| PRTA | Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an … |
| RVU.WA | Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Evogene
A-Score
1-Year Total Return ->
🥈
Immatics
A-Score
1-Year Total Return ->
🥉
Pharming
A-Score
1-Year Total Return ->
4
Prothena
A-Score
1-Year Total Return ->
5
Oxford Nanopore Technologies
A-Score
1-Year Total Return ->
6
